News >

FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML

Jason Broderick
Published: Friday, Nov 10, 2017

Lia Gore, MD

Lia Gore, MD
The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication